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Abstract

The development of new analytical methods for assurance of quality, safety and efficacy of drugs and pharmaceuticals is of great importance because of their use not only as health care products but also life saving substances. The analytical methods assume of great importance due to i) development of new drugs ii) continuous changes in manufacturing processes for existing drugs and iii) setting up of threshold limits for individual and total impurities of drugs by regulatory authorities. Keeping this in view, an attempt was made in the present investigation to develop new analytical methods for some of the important drugs and pharmaceuticals of gastroprokinetic agents, antihypertensive, immunosuppressants and antitussive in nature. All the methods described in the thesis are simple, rapid, reliable and validated. The methods could be used not only for quality control but also for process development of bulk drugs. The work carried out in the present investigation was described in six chapters. 
Chapter 1: Quality, safety and efficacy of drugs 
Chapter 1 gives a brief introduction to quality, safety and efficacy of drugs and pharmaceuticals with some examples of thalidomide, aspirin and hydrocholrothiazide. The origin of impurities, types of different impurities in drugs and pharmaceuticals, impurity profiling, identification of impurities by analytical techniques such as HPLC, LC-MS, GC-MS, LC-NMR and MS were discussed. The pharmacopoeial status, regulatory aspects and analytical methodologies were presented. Statement of the problem, aims and objectives of the present investigation were given at the end of the chapter. All the experimental details were given in the respective chapters. 
Chapter 2 
LC and LC-MS studies of Mosapride citrate dihydrate and its process-related substances 
Mosapride citrate is a novel gastroprokinetic agent, which behaves as a selective 5-HT4 receptor agonist, enhances only the upper gastroprokinetic motor activity and good in treatment of patients of upper gastrointestinal motility disorders. Reversed phase liquid chromatographic studies for monitoring of process related impurities of mosapride citrate dihydrate were described. The formation of process impurities during the synthesis and their characterization by FT-IR, 1HNMR and MS was discussed. The possible process impurities of mosapride citrate dihydrate (VI) viz., N-[2,3-epoxypropyl]phthalimide (I), 2-[(4-fluorobenzyl)amino]ethanol (II), 2-amino-4-(4-fluorobenzyl)morpholine (III), 4-amino-5-chloro-2-ethoxybenzoicacid (IV) and citric acid (V) were separated on a Symmetry C18 column with 28 mM orthophosphoric acid-acetonitrile (72:28 v/v) pH 3.0 with triethylamine as a mobile phase at a flow rate of 1.0 ml/min and the detection at 276 nm using a photo diode array detector (PDA) at 280C. The effects of organic modifier (i,e., acetonitrile % 15 to 45%) and pH (2.5 to 5) on retention were studied. The retention time, relative retention time, number of theoretical plates, asymmetry factors, resolution (Rs>1.5) and wavelength of maximum absorption were measured for VI and its impurities. The optimized conditions were used to determine the impurities present in different batches of bulk drugs of VI. Three impurities (>0.1%) were detected and identified. Citric acid was identified not only by comparison of the retention times (tR=2.45 min.) but also by LC-MS. The LC-MS method was developed and the samples were analyzed in both positive and negative ion modes. In negative ion mode impurities V and VIII gave molecular ions [M-H]-, at m/z 191 and m/z 206, respectively. In positive ion mode VI and impurity VII gave protonated ions [M+H]+, at m/z 422 and m/z 422 respectively.Identical daughter ions were seen. The structures of the impurities were described based on mass spectral fragmentation. The method was validated with respect to accuracy (for impurities, 93.42-101.22% and R.S.D, 0.15-2.25%. recovery in tablets, 99.40-100%, R.S.D≤1.70) precision, linearity (r2≥0.9989), limit of detection and limit of quantitation. The stability of mosapride citrate dihydrate in the mobile phase for a period of 24 h was studied and no significant changes were observed. 
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i) Active ingredient 
Mosapride citrate dihydrate (VI).2H2OClH2NOEtNHNOFOCOOHCOOHCOOHOH 
ii) Related substances 
NOOOFHNFNONH2ClH2NOEtCOOHCOOHCOOHCOOHOHH2NOEtNHNOFOClClH2NOEtClIIIIIIIVVVIIVIIIOH.2H2OCOOHCOOHCOOHOH 
Chapter 3 
Separation, identification and determination of process-related substances of Doxazosin mesylate by reversed-phase HPLC and liquid chromatography-ion trap mass spectrometry 
Doxazosin mesylate chemically known as, (±) 1-(4-amino-6, 7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-l,4-benzodioxin-2-yl)carbonyl]piperazine monomethane sulfonate, is a selective α1–adrenergic blocker belonging to quinazoline family of drugs. It is used in the treatment of hypertension either alone or in combination of diuretics and β-adrenergic receptor antagonists. More recently, it has been found to be effective in the 
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treatment of benign prostatic hyperplasia (BPH). Two i) isocratic and ii) gradient elution methods for monitoring stage 1 and stage 2 products of doxazosin mesylate (XI) were developed. The development of reversed-phase chromatographic methods for separation and determination of impurities originating from the synthesis of 4-amino-2-chloro-6,7-dimethoxyquinazoline (VII, a key intermediate) and doxazosin mesylate (XI) was discussed. The formation of process impurities during synthesis of stage 1 and stage 2 products and their characterization by FT-IR, 1HNMR and MS was discussed. Vanillic acid (I), methyl veratrate (II), methyl 2-nitroveratrate (III), methyl 2-amino veratrate (IV), 2,4-dihydroxy-6,7-dimethoxyquinazoline (V), 2,4-dichloro-6,7-dimethoxyquinazoline (VI) were the potential impurities of VII while catechol (VIII), (±)ethyl 2,3-dihydro-1,4-benzodioxin-2-carboxylate (IX), and (±) N-(2,3-dihydro-1,4-benzodioxin-2-carbonyl)piperazine (X), side products viz., Bis-amide or [(1-(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-4-(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)]piperazine (X') were the potential impurities of XI. Effects of buffer pH and acetonitrile concentration on retention of the compounds was studied. The developed HPLC conditions for 4-amino-2-chloro-6, 7-dimethoxyquinazoline were: 
Isocratic elution for stage 1 products: 
Mobile phase : Ammonium acetate (10 mM in H2O) and acetonitrile (50:50 v/v), pH adjusted to 4.0 with acetic acid . 
Column : Inertsil-ODS 3 ( G.L Sciences Inc., Tokyo, Japan) column ( 25 cm x 4.6 mm id, particle size 5 μm, pore size 100 A0) 
Flow rate : 1.0 ml/min 
Detector : Photo diode array (PDA) 
Wavelength (λmax) : 240 nm 
Temperature : 25°C ± 2°C 
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Gradient elution for stage 2 products: 
Mobile phase : Solvent A (A: ammonium acetate (10 mM in H2O , pH adjusted to 4.0 with acetic acid and solvent B: acetonitrile) was pumped at flow rate of 1.0 ml/min. according to the gradient mode 0 min. 33% B, 0-8 min. 33% B, 8-15 min. 60% B, 15-25 min. 65% B; 25-28 min. 33% B 
Column : Inertsil-ODS 3 (G.L Sciences Inc., Tokyo, Japan) column ( 25 cm x 4.6 mm id, particle size 5 μm, pore size 100 A0) 
Flow rate : 1.0 ml/min 
Detector : Photo diode array (PDA) 
Wavelength (λmax) : 265 nm 
Temperature : 25°C ± 2°C 
The isocratic and gradient HPLC conditions were used to monitor the progress of stage 1 and stage 2 products respectively. The proposed HPLC methods were successfully adopted to determine potential impurities of bulk drugs of different batches of doxazosin mesylate. The unknown impurity (XI') >0.1% detected at tR=2.34 min. was identified by LC-MS/MS. LC-MS analysis was carried out in positive ion mode, where doxazosin mesylate and impurity XI' gave molecular ions [M+H]+ at m/z 452 and 290 respectively. 
6 
Stage 1 products 
MeOHOOHOMeOMeOOMeOMeOMeOOMeONO2MeOMeOOMeONH2NNMeOMeOClClNNMeOMeONH2ClNNMeOMeOOHOHIIIIIIIVVVIVII 
Stage2 products 
OHOHOOOEtOOONONHNNMeOMeONH2ClNNMeOMeONH2OONONCH3SO3HVIIIIXXDoxazosin mesylate, XIVIINNMeOMeONH2NNHOONONXOOOXI' 
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The mass spectral (MS/MS) fragmentation of impurity XI' (Fig. 1) was compared with that of doxazosin mesylate and possible structure viz., 6,7-dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine was proposed. Later it was synthesized and characterized using FT-IR, 1HNMR, and MS spectrometry. The retention time of the synthesized impurity 
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matched well with the impurity detected in final product of XI. It was confirmed finally as 6,7-dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine (XI'). 
Electrospray mass spectral behavior of quinazoline class of compounds was studied. The positive ion ESI mass spectra of five α1-adrenergic receptor compounds displayed abundant [M+H]+and moderately abundant [M+Na]+ ions. The ESI-mass spectra of doxazosin, prazosin and terazosin showed m/z 247 ions as the base peaks, which were formed by the fission of piperazine ring from [M+H]+ ions; which was either insignificant or totally absent in the ESI mass spectra of compounds alfuzosin and tamsulosin. The ESI mass spectra of alfuzosin and tamsulosin showed peaks at m/z 156 and m/z 228 respectively, corresponding to the fission occurring at between carbon and nitrogen (C-N) bond. Doxazosin, prazosin and terazosin showed similar fragmentation pattern, while compounds alfuzosin and tamsulosin showed different mass spectral fragmentation. The developed HPLC methods were validated with respect to accuracy, precision, linearity and limits of detection and quantitation. 
Chapter 4 
Preparative isolation and characterization of Cyclosporin A and related substances by high-performance liquid chromatography, LC-ESI-MS, 1H and 13C NMR spectroscopy 
Cyclosporins are generally produced as secondary metabolites by various fungi imperfecti (Tolypocladium inflatm Gams 1) and ascomycetes. These represent a class of neutral cyclic oligopeptides composed of eleven partially N-methylated amino acids. Cyclosporins exert remarkable biological effects such as antifungal, antiparasitic, anti-inflammatory, and immunosuppressive activities. This chapter describes the reversed and normal phase liquid chromatographic studies for preparative isolation of process related substances of cyclosporin A (CyA). The reversed phase conditions were used for analytical separation and quantitative determination of process related substances of CyA. The normal phase HPLC conditions were used for isolation of process related substances in a preparative mode. 
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The developed HPLC conditions were i) analytical: Inertsil ODS 3 column (250 x 4.6 mm, particle size 5μm), mobile phase consisting of 0.2% orthophosphoric acid-acetonitrile-tert butyl methyl ether (35:61.6:3.4 v/v/v), at a flow rate of 1.20 ml/min, column temperature at 80oC and detection was made at 210 nm; ii) preparative: YMC Pack silica column of 250 x 20 mm, (5μm particle size), n-hexane-2-propanol-methanol (66.5:28.5:5 v/v/v) as mobile phase, at a flow rate of 8.0 ml/min and detection was made at 210 nm.The HPLC method has been successfully adopted to determine potential impurities in bulk drugs of different batches of CyA. Five related substances I, II, III, IV and V <0.50% were detected at RRT=0.78, 0.86, 1.19, 1.27, and 1.37, respectively. 
LC-MS was used to characterize the related substances of CyA. It was carried out in positive ion mode and the impurities I, II, III, IV and V gave molecular ions at m/z, 1188.6, 1188.6, 1204.2, 1216.6 and 1216.6 respectively. The LC-MS data provided only the molecular mass information. Isolation was carried out using normal phase preparative LC. The impurities were isolated from the crude fermented broths of CyA. Fractions were concentrated under high vacuum and about 25-50 mg of each impurity of purity >97% were obtained. These impurities were subjected to UV, FT-IR, NMR and MS. The spectral data were compared with that of the parent compound CyA and the structures were assigned as CyB, CyL, dihydro CyA, CyG and CyD. The experimental spectral data of all the five impurities were exactly matched with reported data available in the literature. The structures of CyA and its related substances are shown as below. 
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OCCHCONH3CCH2CHCH3H3CNCH3CHCHCH3H3CCONR1OCCHCHCHCCH2HH3CHCH3OCH2CCHH3CH3CNCHCOCOOCNCHCH2CHH3CCH3NCH2CH3CH3NHCHHCH3CCH3COHCHCCH2HH3CCH3NCH3NHOCCH3HCNHHCCH3R2OHOCHNH3CMeBmt1L-X2Sar3MeLeu4Val5MeLeu6Ala7D-Ala8MeLeu9MeLeu10MeVal111234541678CRelated substances:If R1=CH3; R2=CH2CH3 or X=Abu, is CyAIf R1=CH3; R2=CH3 or X=Ala, is impurity I (CyB)If R1=H; R2=CH2CH3 and X=Abu is impurity II (CyL)If R1=CH3; R2=CH2CH3 and single bond betwn. C6,C7 is impurity III (dihydro-CyA)If R1=CH3; R2=CH2CH2 CH3 and X=Norval, is impurity IV (CyG)If R1=CH3; R2=CH(CH3)2 or X= Val, is impurity V (CyD)*Bmt=(4R)-4[E-2-butenyl]-4-methyl-L-threonine Abu= L-2-amino butyric acid; Ala=Alanine; Sar= Sorbine; Val= Valine; MeLeu=Methyl Leucine 
Chapter 5 
Development and validation of a liquid chromatographic method for monitoring of reactions involved in synthesis of 4-methoxyphenylacetic acid and impurity profiles of Dextromethorphan hydro bromide 
This chapter includes the development of reversed-phase chromatographic methods for separation and determination of impurities originating from the synthesis of 4-methoxy 
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phenylacetic acid (PMPA, a key intermediate) and dextromethorphan hydrobromide (DEXM). The synthesis, formation of process impurities and characterization of the impurities by FT-IR, 1HNMR, and MS was discussed. 4-Methoxy acetophenone (PMAP), 4-methoxyphenyl acetamide (PMAM), and 4-methoxyphenyl thioacetomorpholide (PMTM) the potential impurities of PMPA and N- (2-Cyclohexenyl ethyl)-2-(4-methoxyphenyl) acetamide (DEX-II), (+) 1-(4-methoxyphenyl)-1,2,3,4,5,6,7,8-octahydro isoquinoline (DEX-III) and (+) N-methyl -(4-methoxyphenyl)-1,2,3,4,5,6,7,8-octahydro isoquinoline (DEX-IV) the potential impurities of DEXM. The effects of buffer pH and acetonitrile concentration on separation of PMPA, DEXM and their related substances were studied and the optimized HPLC conditions were: 
i) For PMPA 
Mobile phase : Potassium dihydrogen orthophosphate (KH2PO4) (10 mM in H2O), acetonitrile and TEA (59.95:40:0.05 v/v), pH adjusted to 3.0 . 
Column : Hypersil C18 (ThermoQuest, Runcorn, UK) column (25 cm x 4.6 mm I.D; particle size 5 μm) 
Flow rate : 1.0 ml/min 
Detector : Photo diode array (PDA) 
Wavelength (λmax) : 280 nm 
Temperature : 25°C ± 2°C 
ii) For DEXM 
Mobile phase : The mobile phase (A: triethylamine (0.1% in H2O , pH adjusted to 3.0 with acetic acid and B: acetonitrile) was pumped at flow rate of 1.0 ml/min. according to the gradient mode 0 min. 40% B, 0-5 min. 40 B, 8-15 min. 100% B, 15-20 min. 40% B; 20-25 min. 40% B 
Column : Kromasil-C18 (Eka Chemicals AB, SE-445 80 Bohus, Sweden) column ( 25 cm x 4.6 mm id, particle size 5 μm) 
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Flow rate : 1.0 ml/min 
Detector : Photo diode array (PDA) 
Wavelength (λmax) : 225 nm 
Temperature : 25°C ± 2°C 
H3COH3CONNH2SOOH3COOHOCH3H3COOPMAPPMTMPMPAPMAM 
OHH3COONHOCH3CONH3COCH3NHH3COH3CONCH3Detxtromethorphan hydrobromide (DEXM)DEX-IIDEX-IIIPMPADEX-IV.HBr 
The developed HPLC methods were validated as per ICH guidelines for accuracy, precision, specificity, linearity, limit of detection, limit of quantitation, robustness and sample solution stability. The two different reaction profiles of PMPA were monitored by the developed HPLC method. The proposed gradient HPLC method has been successfully adopted to determine the potential impurities of bulk drugs of different batches of DEXM. 
Chapter 6 
Enantiospecific resolution of Mosapride citrate and Doxazosin mesylate on polysaccharide based stationary phases connected with ultraviolet and polarimetric detectors in series 
Chiral liquid chromatographic studies of mosapride citrate dihydrate (MSP) and doxazosin mesylate (DXZN) were described. The resolution of mosapride citrate, doxazosin mesylate and their synthetic precursors on Chiralpak AD-H and Chiralcel OD-H 
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columns was studied. Chiralpak AD-H column containing amylose tris-(3,5- dimethylphenylcarbamate) as a stationary phase was found to be well adopted for resolution of enantiomers of MSP, DXZN, and their synthetic precursors when compared to Chiralcel OD-H containing cellulose tris-(3,5-dimethylphenylcarbamate) as a stationary phase. The effects of organic modifiers viz., ethanol, 1-propanol, 2-propanol and temperature on selectivity and resolution was studied. The optimum separation of MSP was obtained on Chiralpak AD-H column using n-hexane-ethanol-triethylamine (80:20:0.3 v/v/v) as a mobile phase, the UV-detector at 276 nm and column temperature at 40oC (Fig. 1). In case of DXZN, n-hexane-ethanol-2-propanol-diethylamine (70:23:7:0.1 v/v/v/v) was used as mobile phase and the UV-detection at 240 nm. The separation was found to be an enthalpy driven processes. The proposed methods were applied to determine the enantiomeric purity of MSP, DXZN in bulk drugs and pharmaceutical formulations. The total recoveries were found to be between 99.20 and 99.60%, respectively. The separation of enantiomers of MSP, DXZN and their synthetic precursors make the chromatographic methods suitable for both qualifying optical purity and isolation of individual enanatiomers. 
The methods are useful for determination of chiral impurities during the process development and reaction monitoring during the synthesis of MSP and DXZN. The advantages of the developed methods include i) separation of the enantiomers of the MSP, DXZN and their synthetic precursors was achieved in a single run, ii) incase of DXZN, the observed elution order R(-)< S(+) could be beneficial for quantitative analysis, since the minor enantiomer eluted first, assuming that the S (+) enantiomers was desired and iii) as the applied chiral stationary phase is available in bulk, it makes the chromatographic methods up scalable for eventual semi preparative purification and production of the desired enantiomers. 


